Drugs that contain Plazomicin Sulfate

1. Drug name - ZEMDRI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9688711 CIPLA USA Antibacterial aminoglycoside analogs
Nov, 2028

(6 years from now)

US8383596 CIPLA USA Antibacterial aminoglycoside analogs
Jun, 2031

(8 years from now)

CN101868472B CIPLA USA Antibacterial Amino Glycoside Analogue
Nov, 2028

(6 years from now)

CN103360440B CIPLA USA Antibacterial Aminoglycoside Analogues
Nov, 2028

(6 years from now)

CN103360440A CIPLA USA Antibacterial Amino Glycoside Analogue
Nov, 2028

(6 years from now)

CN101868472A CIPLA USA Antibacterial Aminoglycoside Analogues
Nov, 2028

(6 years from now)

IN201004165P1 CIPLA USA Antibacterial Aminoglycoside Analogs
Nov, 2028

(6 years from now)

IN282636B CIPLA USA Novel Aminoglycoside Compounds
Nov, 2028

(6 years from now)

EP3150617A1 CIPLA USA Antibacterial Aminoglycoside Analogs
Nov, 2028

(6 years from now)

EP2217610B1 CIPLA USA Antibacterial Aminoglycoside Analogs
Nov, 2028

(6 years from now)

EP3150617B1 CIPLA USA Antibacterial Aminoglycoside Analogs
Nov, 2028

(6 years from now)

EP2217610A1 CIPLA USA Antibacterial Aminoglycoside Analogs
Nov, 2028

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9266919 CIPLA USA Antibacterial aminoglycoside analogs Nov, 2028

(6 years from now)

US8822424 CIPLA USA Antibacterial aminoglycoside analogs Nov, 2028

(6 years from now)

Treatment: Method of using plazomicin to treat bacterial infections

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 500MG BASE/10ML (EQ 50MG BASE/ML) SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.